Related Experiment Videos
Pathophysiology and treatment of single-vessel coronary artery disease
1Division of Cardiology, Georgetown University Medical Center, Washington, DC 20007-2197, USA.
Insights
Optimal treatment for single-vessel coronary artery disease (CAD) remains debated. Current options include medical therapy and revascularization, but individualized approaches and further trials are needed for chronic stable angina management.
Area of Science:
- Cardiology
- Interventional Cardiology
- Clinical Medicine
Background:
- The optimal management strategy for single-vessel coronary artery disease (CAD) with chronic stable angina is not definitively established.
- Therapeutic choices encompass medical management and various coronary revascularization techniques, including coronary artery bypass grafting (CABG) and percutaneous transluminal coronary angioplasty (PTCA).
Purpose of the Study:
- To review the current therapeutic options for single-vessel CAD and chronic stable angina.
- To highlight the controversies and uncertainties surrounding the best treatment approach.
Main Methods:
- Review of existing literature and early studies comparing medical, surgical, and percutaneous transluminal coronary angioplasty (PTCA) treatments.
- Discussion of the limitations of current diagnostic and treatment paradigms, including the impact of new technologies like stents and lipid-lowering therapies.
Main Results:
- Early studies indicated no significant survival difference between medical and surgical treatments for single-vessel disease.
- Percutaneous transluminal coronary angioplasty (PTCA) improves symptoms and quality of life in severe cases, but survival benefits and prevention of future events are not proven.
- Current practices may not align with guidelines, particularly regarding pre-procedural ischemia assessment.
Conclusions:
- Diagnostic and treatment decisions for single-vessel CAD and chronic stable angina should be individualized.
- Further randomized trials are essential to determine the optimal management strategies, considering advancements like stenting and aggressive lipid management.
Abstract:
The optimal treatment of patients with single-vessel coronary artery disease (CAD) and chronic stable angina is controversial. Therapeutic options include medical therapy with pharmacologic agents and/or coronary revascularization via surgery (coronary artery bypass grafting [CABG]), percutaneous transluminal coronary angioplasty (PTCA), and/or other transcatheter techniques. Early studies found no difference in survival between medical and surgical treatment of patients with single-vessel disease and chronic stable angina. Although PTCA has been shown to improve symptoms and quality of life in patients with single-vessel disease and severe symptoms, improvement in survival and prevention of future events are not established and multiple PTCA procedures or subsequent surgical treatment may be necessary. Medical therapy may be preferred in patients with mild or no symptoms. In patients with chronic stable angina, PTCA practice may not be consistent with current guidelines, particularly obtaining laboratory evidence of ischemia before the procedure. Stenoses that may lead to future coronary events cannot be accurately identified by angiography without evidence of ischemia or symptoms. Currently available comparative studies of patients with CAD do not reflect the impact of stent procedures and aggressive lipid lowering. Therefore, diagnostic and treatment options should be individualized in patients with single-vessel disease and chronic stable angina, and additional randomized trials are necessary to determine the optimal management of these patients.